The Role of Colonoscopy in Inflammatory Bowel Disease

Yong Gil Kim; Byung Ik Jang

doi:10.5946/ce.2013.46.4.317

Articles

Page Path: HOME > Clin Endosc > Volume 46(4); 2013 > Article

Focused Review Series: A Perspective: Endoscopy and Imaging in Inflammatory Bowel Disease The Role of Colonoscopy in Inflammatory Bowel Disease: Yong Gil Kim¹, Byung Ik Jang²; Clinical Endoscopy 2013;46(4):317-320.
DOI: https://doi.org/10.5946/ce.2013.46.4.317
Published online: July 31, 2013

¹Institute for Digestive Research, Digestive Disease Center, Department of Internal Medicine, Soonchunhyang University Gumi Hospital, Soonchunhyang University College of Medicine, Gumi, Korea.

²Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.

Correspondence: Byung Ik Jang. Department of Internal Medicine, Yeungnam University College of Medicine, 170 Hyeonchung-ro, Nam-gu, Daegu 705-717, Korea. Tel: +82-53-620-3830, Fax: +82-53-654-8386, jbi@med.yu.ac.kr

• Received: June 20, 2013 • Revised: June 26, 2013 • Accepted: July 16, 2013

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

9,762 Views
90 Download
13 Crossref
14 Scopus

prev next

Full Article

Download PDF

Abstract
INTRODUCTION
THE ROLE OF COLONOSCOPY IN IBD
CONCLUSIONS
NOTES
REFERENCES

Abstract

An endoscopic evaluation, particularly ileocolic mucosal and histological findings, is essential for the diagnosis of inflammatory bowel disease (IBD). The introduction of antitumor necrosis factor agents has changed the therapeutic paradigm of patients with IBD, but an endoscopic evaluation is more important to guide therapeutic decision-making. In the future, endoscopy with a histological evaluation will be increasingly used in patients with IBD. Both Crohn colitis and ulcerative colitis result in an increased incidence of colorectal carcinoma. Thus, surveillance colonoscopy is important to detect early neoplastic lesions. Surveillance ileocolonoscopy has also changed recently from multiple random biopsies to pancolonic dye spraying with targeted biopsies of abnormal areas.
Keywords: Endoscopy; Inflammatory bowel diseases; Crohn disease; Colitis, ulcerative

INTRODUCTION

Inflammatory bowel disease (IBD), which is a heterogeneous group of diseases that can be broadly classified into Crohn disease (CD) and ulcerative colitis (UC), is a chronic idiopathic inflammatory disorder affecting the gastrointestinal tract. Until the late 1990s, the therapeutic goal for IBD was clinical remission.1 However, the introduction of antitumor necrosis factor (TNF) agents has changed the IBD therapeutic paradigm. Accumulated evidence regarding anti-TNF agents in patients with IBD indicates that mucosal healing is an important therapeutic endpoint in clinical trials, and is also used in clinical practice.2 This altered therapeutic paradigm is changing the role of endoscopy in IBD. Additionally, improvements in endoscopy and other devices are changing the methods of assessing response to treatment and surveillance. Herein, we review the recent role of colonoscopy in IBD.

THE ROLE OF COLONOSCOPY IN IBD

Initial diagnosis

Endoscopy, particularly ileocolonoscopy, is the method of choice for initial diagnosis and assessment of the extent of bowel involvement. It allows classification of disease based on endoscopic extent, severity of mucosal disease, and histological features. It also allows an assessment of suspected stenoses in the distal ileum or colon.

The primary reason for endoscopy is to obtain tissue.3 The four histological criteria of IBD are: distortion in crypt architecture, pyloric metaplasia in the terminal ileum, Paneth cells in the left or distal colon, and basal cell plasmacytosis. These criteria define chronic inflammation and are necessary for IBD to be a considered. The presence of a granuloma is not necessary for the diagnosis of IBD. However, because a sarcoidlike granuloma is highly specific for CD, the presence of a granuloma has been used to distinguish between UC and CD.4

A full colonoscopy is rarely needed in cases of acute severe colitis and may be contraindicated.5 A rectal biopsy should be taken for histology even if there are no macroscopic changes. An upper gastrointestinal endoscopy should be considered when dyspepsia coexists. However, the role of small bowel endoscopy remains to be defined.6

Evaluation of therapeutic effect

Mucosal healing on endoscopy is a key prognostic parameter in the management of IBD after introducing anti-TNF agents. Thus, the role of endoscopy for monitoring IBD activity has been highlighted.

Mucosal healing is usually defined as the resolution of visible ulcers on endoscopy. However, no validated definition of mucosal healing exists with respect to endoscopic response or remission of either UC or CD. Mucosal healing has long been recognized as a therapeutic goal in patients with UC because UC is associated with only mucosal inflammation and affects the colon. Mucosal healing is generally defined by the Mayo Clinic endoscopy subscore of 0 (normal, or inactive), as presented in Table 1.7 Endoscopy subscores of 0 or 1 at week 8 have a significantly lower risk of colectomy over the next year, compared to patients with scores of 2 or 3 (p=0.0004). An endoscopy subscore of 0 at week 8 predicted symptom relief at weeks 30 and 54 in 71% and 74%, respectively, compared to 51% and 47% for a score of 1 at week 8. Patients with an endoscopy subscore of 0 at week 8 have a higher rate of steroid-free remission at week 54 than those with a score of 1.8 The mucosal findings on endoscopy, particularly proctosigmoidoscopy, in clinically improved patients with UC are important for therapeutic decision-making.9 Thus, endoscopy with a histological evaluation will be increasingly used in patients with UC.

The Crohn's disease endoscopic index of severity (CDEIS) is the gold standard for assessing CD endoscopic activity (Table 2).10 Definitions of mucosal healing are generally based on the CDEIS, which is presented in Table 2.11 The threshold for endoscopic remission has been set as a CDEIS <6, with other criteria for response (a decrease in CDEIS >5), complete endoscopic remission (CDEIS <3), and mucosal healing (absence of ulcers). The prognosis of CD is independently affected by the presence of deep and extensive ulceration at index colonoscopy.12 Mucosal healing on ileocolonoscopy in patients with CD reduces the likelihood of clinical relapse, the risk of surgery, and hospitalization.13,14 Recently, deep remission has been suggested as a treatment goal in CD, following its use in rheumatoid arthritis.15 Deep remission includes not only symptom control, but also alteration of the biological processes that contribute to the disease, such as progressive structural damage and functional decline. Accomplishing deep remission might be a method of altering the course of CD. The Extend the Safety and Efficacy of Adalimumab through Endoscopic Healing trial empirically defined deep remission as a Crohn's Disease Activity Index <150 and complete mucosal healing.16 In the Stop Infliximab in Patients with Crohn's Disease trial, deep remission was defined as a CDEIS of 0, a calprotectin level >250 mg/g, and an high sensitivity C-reactive protein <5 mg/L.17 These emerging concepts in CD have included mucosal healing as an essential requirement. However, the definitions of deep remission have not been validated.

Ileocolonoscopy might not be enough to evaluate mucosal healing because CD can affect any part of the gastrointestinal tract-from the mouth to the anus-and typically features transmural inflammation. Thus, transsectional imaging is needed to evaluate mucosal healing in cases of CD. A prospective study showed that the magnitude of various quantitative magnetic resonance imaging changes, such as wall thickening, contrast signal intensity, and relative contrast enhancement, are correlated with the severity of endoscopic lesions in patients with CD.18

Surveillance colonoscopy for colitic cancer

Both Crohn colitis and UC increase the incidence of colorectal carcinoma and the need for surveillance colonoscopy. Generally, the incidence of colorectal cancer in patients with UC is 2- to 5-fold higher than that in general population.19 It is widely accepted that patients with Crohn colitis, with a similar extent and duration of colonic involvement, have a similar risk to those with UC.20

Surveillance colonoscopy is important to detect early neoplastic lesions. The surveillance intervals are stratified based on colitic cancer risk. The colitic cancer risk is estimated based on the duration and extent of colitis, coexistence of primary sclerosing cholangitis, family history of colorectal cancer, colonoscopic findings, and histological findings. The surveillance intervals are shown in Table 3.20,21 As surveillance colonoscopy becomes more critical in detection, the technique has evolved. Recently, pancolonic dye spraying or confocal microendoscopy with targeted biopsies of abnormal areas has been recommended.21 However, to use these newer colonoscopic techniques effectively, specialized training is needed. If chromoendoscopy is not used, multiple random biopsies should be taken at regular intervals.

CONCLUSIONS

Endoscopic evaluations for assessment of the response to treatment and for prediction of the course of IBD have remained controversial. An endoscopic examination with histological evaluation allows a careful objective surveillance for colorectal cancer. Endoscopic evaluation of the response to treatment is reasonable if the objective is to guide therapeutic decision-making. Chromoendoscopy with targeted biopsies of abnormal lesions is more appropriate than multiple random biopsies for colorectal cancer surveillance. Monitoring mucosal healing is promising. However, long-term follow-up, prospective studies of anti-TNF agents in patients with IBD are needed.

The authors have no financial conflicts of interest.

REFERENCES

1. Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995;30:699–706.Article PubMed
2. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002;122:512–530.Article PubMed
3. Yusoff IF, Ormonde DG, Hoffman NE. Routine colonic mucosal biopsy and ileoscopy increases diagnostic yield in patients undergoing colonoscopy for diarrhea. J Gastroenterol Hepatol 2002;17:276–280.Article PubMed
4. Tanaka M, Riddell RH, Saito H, Soma Y, Hidaka H, Kudo H. Morphologic criteria applicable to biopsy specimens for effective distinction of inflammatory bowel disease from other forms of colitis and of Crohn's disease from ulcerative colitis. Scand J Gastroenterol 1999;34:55–67.Article PubMed
5. Terheggen G, Lanyi B, Schanz S, et al. Safety, feasibility, and tolerability of ileocolonoscopy in inflammatory bowel disease. Endoscopy 2008;40:656–663.Article PubMed
6. Bourreille A, Ignjatovic A, Aabakken L, et al. Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus. Endoscopy 2009;41:618–637.Article PubMed
7. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625–1629.Article PubMed
8. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011;141:1194–1201.Article PubMed
9. Pineton de Chambrun G, Peyrin-Biroulet L, Lémann M, Colombel JF. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010;7:15–29.Article PubMed PDF
10. Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 2012;61:1619–1635.Article PubMed
11. Mary JY, Modigliani R. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Gut 1989;30:983–989.Article PubMed PMC
12. Allez M, Lemann M, Bonnet J, Cattan P, Jian R, Modigliani R. Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol 2002;97:947–953.Article PubMed
13. Ha C, Kornbluth A. Mucosal healing in inflammatory bowel disease: where do we stand? Curr Gastroenterol Rep 2010;12:471–478.Article PubMed
14. Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut 2007;56:453–455.Article PubMed PMC
15. Mader R, Keystone E. Optimizing treatment with biologics. J Rheumatol Suppl 2007;80:16–24.PubMed
16. Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012;142:1102–1111.Article PubMed
17. Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012;142:63–70.Article PubMed
18. Rimola J, Rodriguez S, García-Bosch O, et al. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease. Gut 2009;58:1113–1120.Article PubMed
19. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526–535.Article PubMed PMC
20. Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010;59:666–689.Article PubMed
21. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60:571–607.Article PubMed

Table 1

Mayo Score Endoscopic Subscore7

Table 2

The Crohn Disease Endoscopic Index of Severity11

Table 3

Surveillance Recommendations for Colitic Cancer20,21

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

YouTube® en español como fuente de información para pacientes con enfermedad inflamatoria intestinal
C.E. Lombo-Moreno, O.M. Muñoz-Velandia, D.G. Fernández-Ávila, J.E. Barahona-Correa, V. López-Ramírez, A. Rodriguez-Varon
Revista de Gastroenterología de México.2024; 89(2): 176. CrossRef
YouTube® in Spanish as a source of information for patients with inflammatory bowel disease
C.E. Lombo-Moreno, O.M. Muñoz-Velandia, D.G. Fernández-Ávila, J.E. Barahona-Correa, V. López-Ramírez, A. Rodriguez-Varon
Revista de Gastroenterología de México (English Edition).2024; 89(2): 176. CrossRef
Memristor-based Bayesian spiking neural network for IBD diagnosis
Xiaowen Li, Qiqiao Wu, Yuanwen Chen, Yang Jin, Jianxia Ma, Jianguo Yang
Knowledge-Based Systems.2024; 300: 112099. CrossRef
Advancements in the use of AI in the diagnosis and management of inflammatory bowel disease
Dalia Braverman-Jaiven, Luigi Manfredi
Frontiers in Robotics and AI.2024;[Epub] CrossRef
Role of MR enterography versus ileo-colonoscopy in the assessment of inflammatory bowel diseases
Rasha Mostafa Mohamed Ali, Aya Fawzy Abd El Salam, Ismail Anwar, Hany Shehab, Maryse Youssef Awadallah
Egyptian Journal of Radiology and Nuclear Medicine.2023;[Epub] CrossRef
HISTOPATHOLOGICAL FEATURES IN RELAPSE OF ULCERATIVE COLITIS.
Saroash Iqbal, Aman Ur Rehman, Nausheen Henna, Zara Madiha, Sahar Moeed, Uzma Aslam
JAIMC: Journal of Allama Iqbal Medical College.2023;[Epub] CrossRef
Prevalence and Risk Factors of Cytomegalovirus Colitis in Inflammatory Bowel Disease Patients in Riyadh, Saudi Arabia: A Tertiary Center Experience
Yazeed Alotaibi, Abed AlLehibi, Abdullah Almtawa, Nawaf Alotaibi, Adel Alghamdi, Saad Alrajhi, Adel AlQutub, Ahmad AlEid, Abdulrhman Alamr, Bashaar Al Ibrahim, Mohammed Alahmari, Hussam Alhamidi, Shameem Ahmad, Fouad Alshammari, Fahad Almotawa, Youssef Al
Saudi Journal of Medicine & Medical Sciences.2023; 11(4): 305. CrossRef
Mango (Mangifera indica L.) polyphenols reduce IL-8, GRO, and GM-SCF plasma levels and increase Lactobacillus species in a pilot study in patients with inflammatory bowel disease
Hyemee Kim, Vinicius P. Venancio, Chuo Fang, Andrew W. Dupont, Stephen T Talcott, Susanne U Mertens-Talcott
Nutrition Research.2020; 75: 85. CrossRef
Can microscopic ileitis in patients with clinically suspected inflammatory bowel disease predict the future?
Fadi Abu Baker, Jesus Alonso Z’cruz De La Garza, Smadar Nafrin, Amir Mari, Muhammed Suki, Baruch Ovadia, Oren Gal, Yael Kopelamn
BMC Gastroenterology.2020;[Epub] CrossRef
Breath Analysis Using eNose and Ion Mobility Technology to Diagnose Inflammatory Bowel Disease—A Pilot Study
Akira Tiele, Alfian Wicaksono, Jiten Kansara, Ramesh P. Arasaradnam, James A. Covington
Biosensors.2019; 9(2): 55. CrossRef
The value of mRNA expression of S100A8 and S100A9 as blood-based biomarkers of inflammatory bowel disease
Tayebeh Azramezani Kopi, Azade Amini Kadijani, Hadi Parsian, Shabnam Shahrokh, Hamid Asadzadeh Aghdaei, Alireza Mirzaei, Hedieh Balaii, Mohammad Reza Zali
Arab Journal of Gastroenterology.2019; 20(3): 135. CrossRef
MR Enterography of Inflammatory Bowel Disease with Endoscopic Correlation
Pankaj Kaushal, Alexander S. Somwaru, Aline Charabaty, Angela D. Levy
RadioGraphics.2017; 37(1): 116. CrossRef
Diagnosing inflammatory bowel disease and differentiating it from potential mimics
Kindra D. Clark-Snustad, Scott D. Lee
Techniques in Gastrointestinal Endoscopy.2016; 18(3): 108. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format: